OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Trial Profile

OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Squalamine (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms MAKO
  • Sponsors Ohr Pharmaceutical
  • Most Recent Events

    • 14 Feb 2018 Status changed from active, no longer recruiting to discontinued company has discontinued further development of squalamine to preserve cash and to evaluatie strategic alternatives to maximize shareholder value, according to an Ohr Pharmaceutical media release.
    • 05 Jan 2018 Results presented in an Ohr Media Release.
    • 05 Jan 2018 Acording to Ohr Pharmaceutical media release, primary endpoint has not been met. (Functional change in visual acuity)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top